| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2023 | -13.37% | Morgan Stanley | $4 → $1.75 | Downgrades | Equal-Weight → Underweight |
| 11/09/2023 | -0.99% | Susquehanna | $3.75 → $2 | Maintains | Neutral |
| 10/20/2023 | -50.5% | Truist Securities | $3 → $1 | Maintains | Sell |
| 08/03/2023 | 98.02% | Morgan Stanley | $4 → $4 | Reiterates | Equal-Weight → Equal-Weight |
| 06/14/2023 | 135.15% | Alembic Global | → $4.75 | Upgrades | Underweight → Neutral |
| 05/15/2023 | 157.43% | Goldman Sachs | $6 → $5.2 | Maintains | Neutral |
| 05/11/2023 | 85.64% | Susquehanna | $3 → $3.75 | Maintains | Neutral |
| 05/10/2023 | 48.51% | Wells Fargo | $2.5 → $3 | Maintains | Underweight |
| 02/17/2023 | — | Wolfe Research | Upgrades | Underperform → Peer Perform | |
| 01/24/2023 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 01/18/2023 | 197.03% | Goldman Sachs | $12 → $6 | Maintains | Neutral |
| 01/10/2023 | 98.02% | Morgan Stanley | → $4 | Reinstates | → Equal-Weight |
| 11/07/2022 | 48.51% | Wells Fargo | $3.25 → $3 | Maintains | Underweight |
| 10/11/2022 | 98.02% | Wolfe Research | → $4 | Initiates Coverage On | → Underperform |
| 09/09/2022 | 98.02% | Bernstein | → $4 | Downgrades | Market Perform → Underperform |
| 08/18/2022 | 147.52% | B of A Securities | $7 → $5 | Maintains | Underperform |
| 08/05/2022 | 147.52% | Truist Securities | → $5 | Downgrades | Hold → Sell |
| 06/21/2022 | 98.02% | Wells Fargo | → $4 | Initiates Coverage On | → Underweight |
| 05/09/2022 | 296.04% | Truist Securities | $24 → $8 | Downgrades | Buy → Hold |
| 05/06/2022 | 296.04% | Canaccord Genuity | $36 → $8 | Downgrades | Buy → Hold |
| 02/28/2022 | 395.05% | Morgan Stanley | $16 → $10 | Maintains | Underweight |
| 02/24/2022 | 1088.12% | Truist Securities | $32 → $24 | Maintains | Buy |
| 02/24/2022 | 345.54% | Susquehanna | $22 → $9 | Maintains | Neutral |
| 01/14/2022 | 1682.18% | Canaccord Genuity | $44 → $36 | Maintains | Buy |
| 10/18/2021 | 642.57% | UBS | $26 → $15 | Downgrades | Neutral → Sell |
| 08/31/2021 | 1533.66% | Jefferies | → $33 | Initiates Coverage On | → Buy |
| 08/11/2021 | 1137.62% | Morgan Stanley | → $25 | Downgrades | Equal-Weight → Underweight |
| 07/13/2021 | 2276.24% | Canaccord Genuity | $35 → $48 | Maintains | Buy |
| 07/06/2021 | 2127.72% | UBS | $36 → $45 | Downgrades | Buy → Neutral |
| 06/30/2021 | 1929.7% | B of A Securities | → $41 | Downgrades | Buy → Underperform |
| 06/28/2021 | — | Alembic Global | Downgrades | Overweight → Neutral | |
| 05/26/2021 | 1632.67% | Canaccord Genuity | → $35 | Initiates Coverage On | → Buy |
| 05/25/2021 | 1137.62% | Morgan Stanley | $30 → $25 | Maintains | Equal-Weight |
| 05/24/2021 | — | Alembic Global | Upgrades | Neutral → Overweight | |
| 05/21/2021 | 1682.18% | UBS | $40 → $36 | Upgrades | Neutral → Buy |
| 05/11/2021 | 1533.66% | Credit Suisse | $42 → $33 | Maintains | Outperform |
| 04/13/2021 | 1236.63% | Bernstein | → $27 | Initiates Coverage On | → Market Perform |
| 03/17/2021 | 2375.25% | Truist Securities | → $50 | Initiates Coverage On | → Buy |
| 03/16/2021 | 2375.25% | Truist Securities | → $50 | Initiates Coverage On | → Buy |
| 03/03/2021 | 2375.25% | B of A Securities | $35 → $50 | Maintains | Buy |
| 02/10/2021 | 2474.26% | UBS | $35 → $52 | Downgrades | Buy → Neutral |
| 02/01/2021 | 1385.15% | Morgan Stanley | $24 → $30 | Downgrades | Overweight → Equal-Weight |
| 10/23/2020 | 840.59% | Goldman Sachs | → $19 | Initiates Coverage On | → Neutral |
| 09/28/2020 | 890.1% | Susquehanna | → $20 | Initiates Coverage On | → Positive |
| 09/28/2020 | 1632.67% | B of A Securities | → $35 | Initiates Coverage On | → Buy |
| 09/09/2020 | 1088.12% | Credit Suisse | → $24 | Reinstates | → Outperform |
| 09/08/2020 | 1137.62% | UBS | → $25 | Initiates Coverage On | → Buy |
| 08/31/2020 | 989.11% | Cowen & Co. | → $22 | Initiates Coverage On | → Outperform |
| 06/10/2020 | 989.11% | Credit Suisse | $25 → $22 | Maintains | Neutral |
| 03/24/2020 | 1088.12% | Morgan Stanley | $30 → $24 | Upgrades | Equal-Weight → Overweight |
| 02/27/2020 | 1137.62% | Credit Suisse | $15 → $25 | Downgrades | Outperform → Neutral |
| 02/27/2020 | 1385.15% | Morgan Stanley | $22 → $30 | Downgrades | Overweight → Equal-Weight |
| 12/09/2019 | 989.11% | Morgan Stanley | → $22 | Initiates Coverage On | → Overweight |
| 11/21/2019 | 515.35% | Credit Suisse | → $12.43 | Initiates Coverage On | → Outperform |
| 11/05/2019 | — | Vertical Research | Initiates Coverage On | → Buy |
What is the target price for Virgin Galactic Hldgs (SPCE)?
The latest price target for Virgin Galactic Hldgs (NYSE: SPCE) was reported by Morgan Stanley on November 22, 2023. The analyst firm set a price target for $1.75 expecting SPCE to fall to within 12 months (a possible -13.37% downside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Virgin Galactic Hldgs (SPCE)?
The latest analyst rating for Virgin Galactic Hldgs (NYSE: SPCE) was provided by Morgan Stanley, and Virgin Galactic Hldgs downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for Virgin Galactic Hldgs (SPCE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Virgin Galactic Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Virgin Galactic Hldgs was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.
Is the Analyst Rating Virgin Galactic Hldgs (SPCE) correct?
While ratings are subjective and will change, the latest Virgin Galactic Hldgs (SPCE) rating was a downgraded with a price target of $4.00 to $1.75. The current price Virgin Galactic Hldgs (SPCE) is trading at is $2.02, which is out of the analyst's predicted range.